68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor–
expressing tumors. Integrating this imaging data effectively in patient care requires the …

Our purpose was to evaluate the safety and efficacy of 68Ga-DOTATATE PET/CT compared
with 111In-pentetreotide imaging for diagnosis, staging, and restaging of pulmonary and …

111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scintigraphy is currently the
nuclear medicine imaging modality of choice for identifying neuroendocrine tumors …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog,
68Ga-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N ″, N ″′-tetraacetic acid-d …

Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly
used for managing patients with neuroendocrine tumors. The objective of this study was to …

Neuroendocrine tumors (NETs) are rare group of neoplasms arising from nervous and
endocrine systems. Somatostatin analogue imaging is a functional imaging modality of …

Radiopharmaceuticals targeting cell surface expression of somatostatin receptors (SSTRs)
are particularly useful in the evaluation of neuroendocrine tumors. Gallium-68 DOTA-Tyr 3 …

Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …